Abbott Laboratories (ABT) Expected to Post Quarterly Earnings on Wednesday

Key Points

• Abbott Laboratories is expected to report Q3 2026 results before the market opens on October 21. Analysts project $1.42 in earnings per share and $13.00 billion in revenue, compared with company guidance of $1.38–$1.46 EPS.
• Abbott exceeded estimates in its previous quarter, earning $1.31 per share on $12.59 billion in revenue, with sales up 13% year over year. Analysts expect full-year 2026 EPS of approximately $5.52.
• The company declared a quarterly dividend of $0.63 per share, equivalent to a 2.5% annualized yield. Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $118.88.

Abbott Laboratories (NYSE:ABT - Get Free Report) is expected to release its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect the company to post earnings of $1.42 per share and revenue of $13.00 billion for the quarter. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 9:00 AM ET.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm's quarterly revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 earnings per share. On average, analysts expect Abbott Laboratories to post $5.52 EPS for the current fiscal year and $6.08 EPS for the next fiscal year.

Abbott Laboratories Stock Up 0.9%

Shares of Abbott Laboratories stock opened at $102.71 on Wednesday. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $133.34. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company's 50 day moving average is $106.08 and its 200 day moving average is $98.27. The company has a market cap of $177.72 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 1.89 and a beta of 0.59.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories's payout ratio is 81.55%.

Analyst Ratings Changes

ABT has been the subject of a number of research reports. Citigroup boosted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, July 17th. Rothschild & Co Redburn upgraded Abbott Laboratories from a "neutral" rating to a "buy" rating and raised their price target for the stock from $119.00 to $127.00 in a research note on Friday, October 2nd. Wells Fargo & Company lifted their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price objective for the company in a research report on Thursday, August 13th. Finally, Weiss Ratings raised Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, September 18th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.88.

About Abbott Laboratories

Abbott Laboratories NYSE: ABT is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott's medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.